TipRanks
Solid Biosciences (SLDB)
NASDAQ:SLDB
US Market
Want to see SLDB full AI Analyst Report?

Solid Biosciences (SLDB) Drug Pipeline

1,597 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Sgt-003
Duchenne Muscular Dystrophy
Phase III
Not Yet Recruiting
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Aug 29, 2025
―
Sgt-501
Catecholaminergic Polymorphic Ventricular Tachycardia
Phase I
Not Yet Recruiting
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Aug 22, 2025
―
Sgt-212
Friedreich's Ataxia (Fa)
Phase I
Not Yet Recruiting
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
Aug 22, 2025
―
Sgt-003
Duchenne Muscular Dystrophy
Phase I/II
Recruiting
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Nov 14, 2023
―
Sgt-001
Duchenne Muscular Dystrophy
Phase I/II
Active Not Recruiting
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
Dec 05, 2017
―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Solid Biosciences (SLDB) have in its pipeline
      SLDB is currently developing the following drugs: Sgt-003, Sgt-501, Sgt-212. These drug candidates are in various stages of clinical development as the company works toward FDA approval.